Orthocell announces further validation of 'Cell Factory' concept for generation of bone, cartilage

Regenerative medicine company Orthocell Limited is pleased to announce further validation of ‘Cell Factory’ concepts for generating tissue specific growth factors and protein’s to aid in the healing and regeneration of bone, tendon and cartilage.

Leading Swedish and Indian researchers from the Department of Orthopedics, Clinical Sciences, Lund University, Sweden and Department of Biological Sciences and Bioengineering, Indian Institute of Technology Kanpur, India published in the respected journal of "ACS Applied Materials and Interfaces" confirmed that protein’s and bio-active molecules (growth factors) derived from a ‘cell factory’ have a positive effect on bone regeneration. It lead to early bone defect healing in an animal model when combined with a collagen scaffold (in this case gelatin).

This is another important validation of the potential of Orthocell’s innovative intellectual property around the generation of ‘tissue specific’ growth factors for the regeneration of bone and cartilage and follows on from the validation of the ‘cell factory’ derived protein’s for cartilage injuries that was announced by Orthocell in May 2015, as well as the granting of the United States ‘Cell Factory’ patent previously announced in January 2016.

Orthocell Managing Director Mr Paul Anderson commented:

These studies support the value of our ‘Cell Factory’ derived growth factors pipeline and also provides another step towards the potential for off the shelf tissue specific growth factors. As the population ages and bone and joint conditions become more prevalent, doctors and patients are seeking out treatments to alleviate symptoms that affect their mobility and quality of life.

The publication of the article in the Journal ACS Applied Materials and Interfaces further strengthens Orthocell’s ‘cell factory’ growth factor pipeline opportunities in the regeneration of bone and cartilage and provides another stepping stone towards the clinical testing and development of these products to treat degenerative and acute bone and cartilage injuries.